Monopar Therapeutics has initiated patient enrollment in the P-I study to investigate the safety and dosimetry of MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) among patients (n=12) with advanced cancer
The study was based on the preclinical results demonstrating MNPR-101’s specific and durable tumor uptake in human cancer xenograft models. The data also showed the MNPR-101’s anti-tumor activity when combined with radioisotopes
The company anticipates the expansion of the trial or a new trial to investigate the effectiveness of MNPR-101 linked with Ac-225 for advanced cancer treatment if it shows better tumor uptake, biodistribution and safety outcomes in the P-I study
Ref: Monopar Therapeutics | Image: Monopar Therapeutics
Related News:- Immix Biopharma Reports the Patient Dosing in P-Ib/IIa Trial of IMX-110 + Tislelizumab for the Treatment of Advanced Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
